Multiple Myeloma
Multiple Myeloma
Advertisement
Patrick DalyMultiple Myeloma | September 19, 2023
Higher creatinine levels and decompression surgery without fusion were linked to complications after spinal surgery in MM.
Read More
Patrick DalyMultiple Myeloma | September 19, 2023
The phase 1/2 MajesTEC-1 study established a recommended dose for subcutaneous teclistamab in relapsed or refractory MM.
Patrick DalyMultiple Myeloma | September 19, 2023
Prior allogeneic stem cell transplantation did not appear to impact the safety and efficacy of cilta-cel treatment for MM.
Patrick DalyMultiple Myeloma | August 21, 2023
IMWG multiple myeloma treatment guidelines informed by studies with a major lack of Black patients, study finds.
Patrick DalyMultiple Myeloma | August 1, 2023
Daratumumab added to carfilzomib-lenalidomide-dexamethasone triplet therapy for multiple myeloma improved MRD and survival.
Cailin ConnerBlood Cancers | July 31, 2023
Age, marital status, and tumor site were independent prognostic factors for extramedullary multiple myeloma.
Cailin ConnerBlood Cancers | July 31, 2023
BMI before and at MM diagnosis did not significantly impact survival.
Cailin ConnerBlood Cancers | July 24, 2023
An educational intervention increased provider confidence in aligning multiple myeloma treatment decisions.
Patrick DalyMultiple Myeloma | July 19, 2023
Elotuzumab combination therapy had promising activity and tolerability for patients with multiple myeloma in first relapse.
Patrick DalyMultiple Myeloma | July 5, 2023
Selinexor-based triplet regimens were effective in patients with multiple myeloma who were refractory to anti-CD38 therapies.
Cailin ConnerBlood Cancers | July 1, 2023
Patients with multiple myeloma who are treated at academic centers have significantly improved survival rates.
Tamara ThomasMultiple Myeloma | June 8, 2023
Normal neutrophil levels may be lower for Black versus whites, leading to disparity in multiple myeloma trial enrollment,
Patrick DalyMultiple Myeloma | June 8, 2023
Higher-dose cyclophosphamide worsened overall survival and platelet recovery in patients with MM undergoing CAR-T therapy.
Patrick DalyMultiple Myeloma | June 8, 2023
Cilta-cel showed reduced disease progression and death versus standard care in patients with lenalidomide-refractory MM.
Patrick DalyMultiple Myeloma | June 8, 2023
Direct oral anticoagulants were non-inferior to low-molecular-weight heparin for preventing VTE in patients with MM.
Patrick DalyMultiple Myeloma | June 8, 2023
Radiation therapy neither improved nor halted neurologic deterioration in patients with spinal cord compression due to MM.
Patrick DalyMultiple Myeloma | April 12, 2023
Based on meta-analysis, researchers reported β2 microglobulin level may predict thrombosis in patients with multiple ...
Patrick DalyMultiple Myeloma | April 12, 2023
Study finds upregulation of CD138+ plasma miR-25 is significantly common and predicts poor treatment response in MM.
Patrick DalyMultiple Myeloma | April 12, 2023
Researchers supported the use of D-VTd over VRd for induction therapy in multiple myeloma after comparing outcome data.
Patrick DalyMultiple Myeloma | April 12, 2023
Predictive model flags patients with multiple myeloma that have increased risk of cardiovascular adverse events.
Advertisement
Advertisement
Latest News

October 3, 2023

Advertisement